Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements review located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://tariqc008jrl0.daneblogger.com/profile